Literature DB >> 27464317

Cardiometabolic Risks in Schizophrenia and Directions for Intervention, 1: Magnitude and Moderators of the Problem.

Chittaranjan Andrade1.   

Abstract

Patients with schizophrenia have increased prevalence rates for many cardiac risk factors. As an example, the metabolic syndrome is common in schizophrenia, with elevated rates for the syndrome and its components evident in first-episode schizophrenia patients, itself. These rates are further elevated in multiepisode patients. Weight gain is a clinical marker of cardiometabolic risk. Antipsychotic drug treatment may drive at least part of the increased cardiometabolic risk; the effects are externally evident in the form of weight gain, with different drugs having different effects on weight and metabolic parameters. Finally, sedentariness and smoking are 2 common behaviors that increase cardiometabolic risks in schizophrenia. It is important for psychiatrists who treat schizophrenia to evaluate the cardiometabolic risks in their patients so that appropriate lifestyle and pharmacologic interventions can be planned. © Copyright 2016 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27464317     DOI: 10.4088/JCP.16f10997

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  4 in total

1.  Amisulpride Switching in Schizophrenic Patients Who Showed Suboptimal Effect and/or Tolerability to Current Antipsychotics in a Naturalistic Setting: An Explorative Study.

Authors:  Yongmin Kim; Sheng-Min Wang; Kyung-Phil Kwak; Ho-Kyoung Yoon; Chi-Un Pae; Jung-Jin Kim; Won-Myong Bahk
Journal:  Clin Psychopharmacol Neurosci       Date:  2016-11-30       Impact factor: 2.582

2.  Cholesterol and Mental Health: A Balanced Perspective.

Authors:  Vikas Menon; Abhishek Ghosh; Chittaranjan Andrade
Journal:  Indian J Psychol Med       Date:  2017 Sep-Oct

3.  The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study.

Authors:  Ying Liang; Xin Yu
Journal:  Neuropsychiatr Dis Treat       Date:  2017-04-21       Impact factor: 2.570

4.  Switching Antipsychotics to Blonanserin in Patients with Schizophrenia: An Open-label, Prospective, Multicenter Study.

Authors:  Young Sup Woo; Bo-Hyun Yoon; Bong-Hee Jeon; Jeong Seok Seo; Beomwoo Nam; Sang-Yeol Lee; Young-Myo Jae; Sae-Heon Jang; Hun Jeong Eun; Seung-Hee Won; Kwanghun Lee; Jonghun Lee; Won-Myong Bahk
Journal:  Clin Psychopharmacol Neurosci       Date:  2019-08-31       Impact factor: 2.582

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.